GENEVA -- An oral reversible Bruton tyrosine kinase inhibitor known as PRN1008 showed promising efficacy and safety for the treatment of pemphigus vulgaris in an interim analysis of an ongoing small-to-date, open-label phase 2 study according to DeDee Murrell, MD.
PRN1008 is a highly potent and selective inhibitor of Bruton tyrosine kinase (BTK), an enzyme that plays a major role in the signaling pathway running downstream from B cells to the B-cell receptors found on most white blood cells with the exception of T cells and plasma cells.
Seventy-five percent of Bruton tyrosine kinase receptors were occupied by PRN1008 by day 2 of the study, confirming earlier studies in canine models of pemphigus.
It was reported yesterday that the US Food and Drug Administration (USFDA) has granted priority review to AstraZeneca, an Anglo-Swedish multinational pharmaceutical and biopharmaceutical company, over a new drug application for its Bruton tyrosine kinase
Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase
(BTK) inhibitor in development for the treatment of multiple B-cell cancers.
Ibrutinib is a bruton tyrosine kinase
(BTK) inhibitor approved for B cell malignancies.
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase (Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.
Keywords: Bruton type agammaglobulinemia, Bruton tyrosine Kinase mutation, Whole exome sequencing, Diarrhoea.
Early changes in cytokines, chemokines, and indices of bone metabolism from phase 2 study of Bruton tyrosine kinase
(Btk) inhibitor, Ibrutinib (PCI-32765) in subjects with relapsed or relapsed/refractory multiple myeloma (MM)
The product is a proprietary Bruton tyrosine kinase
inhibitor intended to treat B-cell malignancies.
23 October 2014 - US cancer genetic testing service provider NeoGenomics Inc (NASDAQ:NEO) disclosed Thursday the launch of new tests for the detection of mutations in the Bruton tyrosine kinase
(BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors, as well as the launch of a lymphoma profiling test predicting susceptibility to BTK inhibitors and testing for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
The collaboration will see Abbott developing a FISH-based test to identify high-risk CLL patients who have a deletion within a specific chromosome (chromosome 17p (del17p)) and may respond to ibrutinib, an oral, small molecule inhibitor of Bruton tyrosine kinase